Abstract
Malignant melanoma is one of the most common causes of cancer and cancer deaths in young people. Until few years ago, scarce drugs have proven efficacy in metastatic setting. However, in the recent years, the treatment of metastatic malignant melanoma has undergone the incorporation of effective treatment such as immunotherapy, the use of tyrosine kinase inhibitors and the emergence of other cytostatic compounds, like the nanoparticles. This review aims to propose a standardization to classify the different types of nanoparticles, according to chemical aspects, and update the clinical research with nanoparticles and their use in melanoma field.
Keywords: Cancer, classification, melanoma, nab-paclitaxel, nanoparticles.
Current Medicinal Chemistry
Title:Nanoparticles in Melanoma
Volume: 21 Issue: 32
Author(s): M.A. Berciano-Guerrero, A. Montesa-Pino, G. Castaneda-Penalvo, L. Munoz-Fernandez and J. Rodriguez-Flores
Affiliation:
Keywords: Cancer, classification, melanoma, nab-paclitaxel, nanoparticles.
Abstract: Malignant melanoma is one of the most common causes of cancer and cancer deaths in young people. Until few years ago, scarce drugs have proven efficacy in metastatic setting. However, in the recent years, the treatment of metastatic malignant melanoma has undergone the incorporation of effective treatment such as immunotherapy, the use of tyrosine kinase inhibitors and the emergence of other cytostatic compounds, like the nanoparticles. This review aims to propose a standardization to classify the different types of nanoparticles, according to chemical aspects, and update the clinical research with nanoparticles and their use in melanoma field.
Export Options
About this article
Cite this article as:
Berciano-Guerrero M.A., Montesa-Pino A., Castaneda-Penalvo G., Munoz-Fernandez L. and Rodriguez-Flores J., Nanoparticles in Melanoma, Current Medicinal Chemistry 2014; 21(32) . https://dx.doi.org/10.2174/0929867321666140716092512
DOI https://dx.doi.org/10.2174/0929867321666140716092512 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology The Genetic Basis of Kidney Cancer: Why is Tuberous Sclerosis Complex Often Overlooked?
Current Molecular Medicine Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Preface
Current Cancer Drug Targets Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine The Possible Role of Saponin in Type-II Diabetes- A Review
Current Diabetes Reviews Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn
Current Immunology Reviews (Discontinued) Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Tyrosinase Activated Melanoma Prodrugs
Anti-Cancer Agents in Medicinal Chemistry Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy